SRPT
Sarepta Therapeutics, Inc.
SRPT offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over SRPT overall, supported by lower modeled downside and stronger modeled upside.
SRPT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Healthy | |
| Weak |
SRPT's cash flow is currently healthy, and its profitability is stable, but its revenue and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
SRPT PE Valuation
SRPT has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
SRPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect SRPT's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over SRPT on the outlook, with more favorable earnings and revenue expectations.
SRPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$1.58 |
| Q2 2026 | -$2.90 | -$2.09 |
| Q1 2026 | -$0.96 | +$1.67 |
| Q4 2025 | -$8.44 | -461% |
| Q3 2025 | -$2.95 | -288% |
| Q2 2025 | -$0.81 | -205% |
| Q1 2025 | -$2.63 | -712% |
| Q4 2024 | $2.34 | +$8.14 |
SRPT is still losing money, but far less than before: $1.37 per share over the past year, against $12.69 at its worst in early 2023.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over SRPT on earnings quality, reporting a profit while its opponent remains loss making.
SRPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $381.4M | -4.5% |
| Q2 2026 | $401.3M | -34% |
| Q1 2026 | $730.8M | -1.9% |
| Q4 2025 | $442.9M | -33% |
| Q3 2025 | $399.4M | -15% |
| Q2 2025 | $611.1M | +68% |
| Q1 2025 | $744.9M | +80% |
| Q4 2024 | $658.4M | +66% |
SRPT's revenue has slid since its 2025 peak: $381M last quarter, down 4.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.4% | +24 points |
| Q2 2026 | 3.3% | -16 points |
| Q1 2026 | 49% | +89 points |
| Q4 2025 | -93% | -118 points |
| Q3 2025 | -26% | -31 points |
| Q2 2025 | 19% | +19 points |
| Q1 2025 | -40% | -49 points |
| Q4 2024 | 25% | +18 points |
SRPT's operating margin was −2.4% last quarter, up 24 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over SRPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over SRPT on profitability, with a higher operating margin.
SRPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57M | +$94.6M |
| Q2 2026 | $196.5M | -14% |
| Q1 2026 | -$204.8M | +$422.3M |
| Q4 2025 | $127.6M | +136% |
| Q3 2025 | -$37.5M | +$70.4M |
| Q2 2025 | $229.5M | +$243.8M |
| Q1 2025 | -$627.1M | -$352.6M |
| Q4 2024 | $54M | +$127.7M |
SRPT has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
SRPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +499K shares |
| 1 year | +5.7% | +5.7M shares |
| 3 years | +19% | +17M shares |
| 5 years | +36% | +28M shares |
SRPT has 106M diluted shares, up 5.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over SRPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
SRPT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 89.5x | High |
| Q2 2025 | -12.7x | Net Cash |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | 8.6x | High |
| Q2 2024 | 10.8x | High |
SRPT's net debt is more than 20 years of its operating earnings (EBITDA), up from 11 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
SRPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 26.2 | Neutral |
SRPT's weekly RSI is 42 (neutral) and its Stochastic is 26 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
SRPT PE vs Healthcare Sector
| Metric | SRPT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SRPT has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
SRPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.7 | 9.3% below |
| 20 week MA | $18.2 | 12% below |
| 50 week MA | $18.9 | 15% below |
| 100 week MA | $35.3 | 55% below |
| 200 week MA | $78.9 | 80% below |
SRPT is in a downtrend: it's below all five of its weekly moving averages, and 80% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over SRPT on trend strength, trading above more of its moving averages.
SRPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $129.8 | $175.0 | +35% |
| 2021 | $175.0 | $91.6 | -48% |
| 2022 | $91.6 | $130.0 | +42% |
| 2023 | $130.0 | $96.4 | -26% |
| 2024 | $96.4 | $121.5 | +26% |
| 2025 | $121.5 | $22.1 | -82% |
| 2026 YTD | $22.1 | $16.0 | -28% |
SRPT has finished lower in three of the last six years. It's down 28% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over SRPT on returns for 2026, with the stronger performance.